APA

Even C., Lassen U., Merchan J., Le Tourneau C., Soria J., Ferte C., Ricci F., Diener J. T., Yuen E., Smith C., Oakley G. J., Benhadji K. A. & Massard C. (20210303). Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma. : Investigational new drugs.

Chicago

Even C, Lassen U, Merchan J, Le Tourneau C, Soria J-C, Ferte C, Ricci F, Diener J T, Yuen E, Smith C, Oakley G J, Benhadji K A and Massard Christophe. 20210303. Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma. : Investigational new drugs.

Harvard

Even C., Lassen U., Merchan J., Le Tourneau C., Soria J., Ferte C., Ricci F., Diener J. T., Yuen E., Smith C., Oakley G. J., Benhadji K. A. and Massard C. (20210303). Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma. : Investigational new drugs.

MLA

Even C, Lassen U, Merchan J, Le Tourneau C, Soria J-C, Ferte C, Ricci F, Diener J T, Yuen E, Smith C, Oakley G J, Benhadji K A and Massard Christophe. Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma. : Investigational new drugs. 20210303.